Attached files
file | filename |
---|---|
8-K - Innovation Pharmaceuticals Inc. | specialreportacc_8k.htm |
BAKER TILLY
formerly
HOLTZ RUBENSTEIN REMINICK
Baker Tilly Virchow Krause, LLP
One Penn Plaza- Suite 3000
New York, NY 10119
Tel 212-697-6900
June 5, 2013
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
RE: Cellceutix Corporation CIK #000-52321
Dear Sir or Madam:
Effective as of June 1, 2013 we are the successor to Holtz Rubenstein Reminick LLP (HRR), which was the independent registered public accounting firm of Cellceutix Corporation (the Company).
We have read the statements made by the Company pursuant to Item 4.01 of Form 8-K, which we understand will be filed with the Securities and Exchange Commission as part of the Form 8-K dated June 5, 2013. We agree with the Companys statements concerning HRR and our firm in such Form 8-K.
Sincerely,
/S/BAKER TILLY VIRCHOW KRAUSE, LLP